BioNTech Valuation Multiples

BioNTech Overview

About BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Founded

2008

HQ

Employees

6.8K

Website

biontech.de

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: ($1B)

EV

$9B

Valuation Multiples

Multiples.vc

Start free trial

BioNTech Financials

BioNTech reported last 12-month revenue of $3B and negative EBITDA of ($1B).

In the same LTM period, BioNTech generated $2B in gross profit, ($1B) in EBITDA losses, and had net loss of ($1B).

BioNTech P&L

In the most recent fiscal year, BioNTech reported revenue of $3B and EBITDA of ($770M).

BioNTech expects next 12-month revenue of XXX and NTM EBITDA of XXX

BioNTech Stock Performance

BioNTech has current market cap of $26B, and enterprise value of $9B.

BioNTech's stock price is $102.92.

BioNTech Valuation Multiples

BioNTech trades at 2.8x EV/Revenue multiple, and (7.1x) EV/EBITDA.

BioNTech Financial Valuation Multiples

As of April 18, 2026, BioNTech has market cap of $26B and EV of $9B.

Equity research analysts estimate BioNTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioNTech has a P/E ratio of (20.3x).

BioNTech Margins & Growth Rates

BioNTech's revenue in the last 12 month declined by (15%).

BioNTech's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.

BioNTech's rule of 40 is (69%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioNTech's rule of X is (102%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

BioNTech Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

BioNTech M&A Activity

BioNTech acquired XXX companies to date.

Last acquisition by BioNTech was on XXXXXXXX, XXXXX. BioNTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

BioNTech Investment Activity

BioNTech invested in XXX companies to date.

BioNTech made its latest investment on XXXXXXXX, XXXXX. BioNTech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).